Schizophrenia is a neurological disorder that disrupts thought, a person’s ability to think and feel clearly. Gradually over time symptoms can worsen, causing psychosis episodes that can be detrimental to somebody’s health. Approximately 24 million people, or 1 in 300 people are diagnosed with schizophrenia. In this blog we’ll talk about the effects of schizophrenia on somebody's life, how schizophrenia can come about, and if CBD could potentially help alleviate the symptoms of schizophrenia.
GW Pharmaceuticals – a UK based biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform – recently announced that it has started Phase 2 clinical trials on a potential drug for the treatment of schizophrenia made from the marijuana compound cannabidiol (CBD).
Cannabidiol (CBD) is a compound that has shown possible benefits in studies on a variety of animal models of mental health, including anxiety, bipo...
Some research has been conducted on the use of CBD to help treat schizophrenia. A study conducted in 2012 suggests that CBD was able to moderately prevent the endocannabinoid, anandamide, from degrading. When anandamide levels are elevated in cerebrospinal fluid, they correlate inversely to the psychotic symptoms of schizophrenia, meaning the symptoms are lessened or in some cases absent.
Research into the effects of cannabinoids, including cannabidiol, continues to progress into exploring an astonishing variety of systems and disorders. Although government restrictions on cannabis research hindered advancement until very recently, currently research has been blooming. If you would like to take part in this research and further our understanding of the biological mechanisms underlying the relief provided by the endocannabinoid system - check out the current clinical trials involving CBD. Many are currently recruiting participants all across the country - you could get involved!